

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8187136/publications.pdf>

Version: 2024-02-01

156  
papers

5,669  
citations

57758

44  
h-index

85541

71  
g-index

163  
all docs

163  
docs citations

163  
times ranked

6032  
citing authors

#	ARTICLE	IF	CITATIONS
1	How to explain the sensitivity of DNA double-strand breaks yield to <sup>125</sup> I position?. International Journal of Radiation Biology, 2023, 99, 103-108.	1.8	3
2	Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. New England Journal of Medicine, 2022, 386, 1860-1861.	27.0	4
3	Diagnostic Rechallenge with <sup>18</sup> F-FCH PET/CT Often Allows Minimally Invasive Parathyroidectomy While Maintaining Exceptional Cure Rates. World Journal of Surgery, 2022, 46, 2409-2415.	1.6	2
4	Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma. Journal of Clinical Oncology, 2021, 39, 943-944.	1.6	2
5	Prospective Comparison of 18-FDG PET/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant. Cancers, 2021, 13, 1938.	3.7	4
6	The EANM practice guidelines for parathyroid imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2801-2822.	6.4	116
7	Improved 18-FDG PET/CT diagnosis of multiple myeloma diffuse disease by radiomics analysis. Nuclear Medicine Communications, 2021, 42, 1135-1143.	1.1	16
8	Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm. Journal of Nuclear Medicine, 2021, 62, 3S-12S.	5.0	13
9	Adjuvant therapy in stage IIIA melanoma. Lancet Oncology, The, 2021, 22, e299.	10.7	4
10	A Bright Future for Nuclear Endocrinology. Journal of Nuclear Medicine, 2021, 62, 1S-2S.	5.0	3
11	Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. New England Journal of Medicine, 2021, 385, 287-287.	27.0	14
12	<sup>68</sup> Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [ <sup>68</sup> Ga]Ga-RM2. Pharmaceutics, 2021, 13, 1160.	4.5	8
13	Targeted radioactive therapy for prostate cancer. Lancet, The, 2021, 398, 487.	13.7	0
14	Predicting outcomes after <sup>177</sup> Lu-PSMA therapy in castration-resistant prostate cancer. Lancet Oncology, The, 2021, 22, e425.	10.7	0
15	Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors. Breast Cancer Research and Treatment, 2021, 190, 403-413.	2.5	2
16	Lutetium- <sup>177</sup> Lu-PSMA-617 for Prostate Cancer. New England Journal of Medicine, 2021, 385, 2494-2496.	27.0	2
17	Prognostic utility of pre-transplantation [ <sup>18</sup> F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma who underwent rituximab, dexamethasone, high-dose cytarabine, carboplatin salvage chemotherapy. British Journal of Haematology, 2020, 188, 268-271.	2.5	3
18	Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine, 2020, 67, 9-19.	2.3	9

#	ARTICLE	IF	CITATIONS
19	Good clinical practice recommendations for the use of PET/CT in oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 28-50.	6.4	85
20	Association of Radioactive Iodine Treatment of Hyperthyroidism With Cancer Mortality: An Unjustified Warning?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1901-e1902.	3.6	10
21	Diagnostic performance of imaging techniques for detecting of local recurrence after prostate brachytherapy. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 323-331.	1.4	1
22	Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim. <i>Journal of Clinical Oncology</i> , 2020, 38, 3237-3238.	1.6	1
23	Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 2869-2880.	1.8	13
24	Silicon-Containing Neuropeptide Analogues as Radiopharmaceuticals for NTS1-Positive Tumors Imaging. <i>Bioconjugate Chemistry</i> , 2020, 31, 2339-2349.	3.6	12
25	Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, e85.	27.0	1
26	Choline PET/CT in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 1394.	3.7	12
27	18FDG-PET/CT Imaging in Breast Cancer Patients with Clinical Stage IIB or Higher. <i>Annals of Surgical Oncology</i> , 2020, 27, 1708-1709.	1.5	1
28	Optimising first-line treatment for metastatic renal cell carcinoma. <i>Lancet, The</i> , 2020, 395, e6.	13.7	1
29	Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2227-2232.	6.4	8
30	Parathyroid Imaging in Patients with Renal Hyperparathyroidism. , 2020, , 35-49.		3
31	Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides. <i>EJNMMI Research</i> , 2020, 10, 16.	2.5	11
32	Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases. <i>EJNMMI Physics</i> , 2020, 7, 33.	2.7	27
33	Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial. <i>JMIR Research Protocols</i> , 2020, 9, e17850.	1.0	3
34	Infections in patients using ventricular-assist devices: Comparison of the diagnostic performance of 18F-FDG PET/CT scan and leucocyte-labeled scintigraphy. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 42-55.	2.1	48
35	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2112-2137.	6.4	208
36	Interim [18F]Fluorodeoxyglucoseâ€“Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2091-2092.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Comparison of the radiolabeled PSMA-inhibitor <sup>111</sup> In-PSMA-617 and the radiolabeled GRP-R antagonist <sup>111</sup> In-RM2 in primary prostate cancer samples. <i>EJNMMI Research</i> , 2019, 9, 52.	2.5	23
38	Recommandations et recommandations. <i>Medecine Nucleaire</i> , 2019, 43, 1-4.	0.2	0
39	Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1721.	4.1	14
40	Early use of abiraterone and radium-223 in metastatic prostate cancer. <i>Lancet Oncology</i> , The, 2019, 20, e229.	10.7	1
41	Thyroid cancer recurrence in the HiLo trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 252.	11.4	0
42	What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1355-1356.	1.6	7
43	PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma. <i>Lancet Oncology</i> , The, 2019, 20, e189.	10.7	0
44	<sup>68</sup> Ga-PSMA-617 Compared With <sup>68</sup> Ga-RM2 and <sup>18</sup> F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e535-e536.	1.3	8
45	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 269-280.	2.9	29
46	Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist <sup>68</sup> Ga-RM2 and <sup>18</sup> F-FDG in breast cancer samples. <i>PLoS ONE</i> , 2019, 14, e0210905.	2.5	27
47	<sup>18</sup> F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 654-657.	6.4	15
48	Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists. <i>Journal of Nuclear Medicine</i> , 2018, 59, 546-547.	5.0	3
49	STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. <i>Journal of Investigative Dermatology</i> , 2018, 138, 58-67.	0.7	47
50	Somatostatin Antagonists for Radioligand Therapy of Nonendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2018, 59, 544-544.	5.0	2
51	Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2124-2125.	1.6	2
52	Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning. <i>Journal of Clinical Oncology</i> , 2018, 36, 1881-1882.	1.6	6
53	Radioactive iodine ablation in low-risk thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 686.	11.4	5
54	Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1401-1407.	5.0	64

#	ARTICLE	IF	CITATIONS
55	Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1254-1257.	6.4	7
56	Performing nuclear medicine examinations in pregnant women. <i>Physica Medica</i> , 2017, 43, 159-164.	0.7	16
57	Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2465-2472.	3.6	59
58	Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. <i>Annales D'Endocrinologie</i> , 2017, 78, 162-175.	1.4	39
59	Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1937-1939.	6.4	0
60	Re. <i>Clinical Nuclear Medicine</i> , 2017, 42, 576.	1.3	1
61	The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. <i>Theranostics</i> , 2017, 7, 1159-1163.	10.0	49
62	On the Role of Interim Fluorine-18 Labeled Fluorodeoxyglucose Positron Emission Tomography in Early-Stage Favorable Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2851-2852.	1.6	6
63	Comparison between Three Promising $\gamma$ -emitting Radionuclides, $^{67}\text{Cu}$ , $^{47}\text{Sc}$ and $^{161}\text{Tb}$ , with Emphasis on Doses Delivered to Minimal Residual Disease. <i>Theranostics</i> , 2016, 6, 1611-1618.	10.0	62
64	New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. <i>Theranostics</i> , 2016, 6, 287-290.	10.0	29
65	Putative Physiopathological Explanation for the "Sock Sign" in Bone Scans. <i>Clinical Nuclear Medicine</i> , 2016, 41, e420-e421.	1.3	0
66	Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection. <i>Journal of Clinical Oncology</i> , 2016, 34, 2673-2674.	1.6	3
67	Hodgkin lymphoma: a negative interim PET cannot circumvent the need for end-of-treatment PET evaluation. <i>British Journal of Haematology</i> , 2016, 175, 652-660.	2.5	23
68	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1949-1956.	5.0	119
69	New Fetal Dose Estimates from $^{18}\text{F}$ -FDG Administered During Pregnancy: Standardization of Dose Calculations and Estimations with Voxel-Based Anthropomorphic Phantoms. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1760-1763.	5.0	24
70	$^{18}\text{F}$ -FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 983-993.	6.4	58
71	$^{18}\text{F}$ -FDG PET/CT for Staging and Restaging of Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 175-265.	5.0	135
72	Dose Deposits from $^{90}\text{Y}$ , $^{177}\text{Lu}$ , $^{111}\text{In}$ , and $^{161}\text{Tb}$ in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 759-764.	5.0	90

#	ARTICLE	IF	CITATIONS
73	Contribution of PET Imaging to the Diagnosis of Septic Embolism in Patients With Pacing Lead Endocarditis. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 283-290.	5.3	60
74	Evaluation of <sup>68</sup> Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1258-1266.	6.4	47
75	<sup>18</sup> F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen. <i>Journal of Nuclear Medicine</i> , 2016, 57, 536-543.	5.0	40
76	Accuracy of Positron Emission Tomography as a Diagnostic Tool for Lead Endocarditis: Design of the Prospective Multicentre ENDOTEP Study. <i>European Cardiology Review</i> , 2016, 11, 25.	2.2	4
77	Comparative effectiveness of [ <sup>18</sup> F]fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. <i>Prostate</i> , 2015, 75, 323-331.	2.3	61
78	Variability of Hepatic <sup>18</sup> F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, e405-e410.	1.3	17
79	Pathological complete response in breast cancer. <i>Lancet, The</i> , 2015, 385, 114.	13.7	8
80	Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. <i>Radiology</i> , 2015, 277, 358-371.	7.3	72
81	The Role of Radionuclide Imaging in the Surgical Management of Primary Hyperparathyroidism. <i>Journal of Nuclear Medicine</i> , 2015, 56, 737-744.	5.0	75
82	High performances of <sup>18</sup> F-fluorodeoxyglucose PET-CT in cardiac implantable device infections: A study of 40 patients. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 787-798.	2.1	50
83	Do clinical, histological or immunohistochemical primary tumour characteristics translate into different <sup>18</sup> F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1682-1691.	6.4	63
84	Baseline Tumor <sup>18</sup> F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2 <sup>-</sup> Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 824-831.	5.0	48
85	<sup>18</sup> F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi-Cancer Site Patient Cohort. <i>Journal of Nuclear Medicine</i> , 2015, 56, 38-44.	5.0	374
86	Breast Cancer Patient With an Uncommon Lymphatic Drainage Evidenced by SPECT/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, e176-e179.	1.3	6
87	Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1650-1657.	5.0	85
88	Additional Diagnostic Value of Hybrid SPECT-CT Systems Imaging in Patients With Differentiated Thyroid Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 305-313.	1.3	5
89	Scintigraphie parathyroïdienne dans l'hyperparathyroïdie primitive: quelques considérations récentes. <i>Medecine Nucleaire</i> , 2014, 38, 208-215.	0.2	0
90	Imaging Secondary Hyperparathyroidism. <i>American Journal of Roentgenology</i> , 2014, 203, W552-W552.	2.2	1

#	ARTICLE	IF	CITATIONS
91	18F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. European Journal of Radiology, 2014, 83, 1925-1933.	2.6	22
92	Variation de la captation h <sup>18</sup> F de 18-FDG dans l'évaluation intermédiaire des lymphomes B diffus à grandes cellules en TEP/TDM. Médecine Nucléaire, 2014, 38, 83-90.	0.2	3
93	Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. European Journal of Cancer, 2014, 50, 1864-1871.	2.8	53
94	Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors. Cancer, 2013, 119, 1960-1968.	4.1	47
95	Gallium-68: Chemistry and Radiolabeled Peptides Exploring Different Oncogenic Pathways. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 85-97.	1.0	34
96	Performance of FDG PET/CT in the Clinical Management of Breast Cancer. Radiology, 2013, 266, 388-405.	7.3	224
97	Comparison Between 18F-FDG PET Image-derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Nuclear Medicine, 2013, 54, 341-349.	5.0	74
98	<sup>18</sup> F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging. Journal of Nuclear Medicine, 2013, 54, 5-11.	5.0	114
99	Cryptorchidism as a potential source of misinterpretation in 18FDG-PET imaging in restaging lymphoma patients. Biomedicine and Pharmacotherapy, 2013, 67, 533-538.	5.6	5
100	Parathyroid Scintigraphy in Renal Hyperparathyroidism. Clinical Nuclear Medicine, 2013, 38, 630-635.	1.3	47
101	Variation of Liver SUV on 18FDG-PET/CT Studies in Women With Breast Cancer. Clinical Nuclear Medicine, 2013, 38, 422-425.	1.3	30
102	Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer. Journal of the National Cancer Institute, 2012, 104, 1879-1887.	6.3	133
103	Triple-Negative Breast Cancer: Early Assessment with <sup>18</sup> F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse. Journal of Nuclear Medicine, 2012, 53, 249-254.	5.0	91
104	Modern Nuclear Imaging for Paragangliomas: Beyond SPECT. Journal of Nuclear Medicine, 2012, 53, 264-274.	5.0	79
105	Parathyroid Scintigraphy. Clinical Nuclear Medicine, 2012, 37, 568-574.	1.3	53
106	Hypoxia Imaging of Uterine Cervix Carcinoma With 18F-FETNIM PET/CT. Clinical Nuclear Medicine, 2012, 37, 1065-1068.	1.3	27
107	FDG PET/CT in Ovarian Cancer. Clinical Nuclear Medicine, 2012, 37, 54-56.	1.3	3
108	Lymphoscintigraphy Can Select Breast Cancer Patients for Internal Mammary Chain Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1081-1088.	0.8	37



#	ARTICLE	IF	CITATIONS
109	Backscatter x-ray machines at airports are safe. <i>Medical Physics</i> , 2012, 39, 4649-4652.	3.0	2
110	Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsyâ€”FDG-PET/CT. <i>PET Clinics</i> , 2011, 6, 9-25.	3.0	6
111	Monte Carlo Simulation of Electron Dose from <sup>131</sup> I-Targeted Tumor Cells Within a Heterogeneous Tumor. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 135-140.	1.0	1
112	Correlation of high <sup>18</sup> F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 426-435.	6.4	337
113	Metastatic Renal Cell Carcinoma: Relationship Between Initial Metastasis Hypoxia, Change After 1 Month's Sunitinib, and Therapeutic Response: An <sup>18</sup> F-Fluoromisonidazole PET/CT Study. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1048-1055.	5.0	82
114	Radiation Risk from Airport X-ray Backscatter Scanners: Should We Fear the Microsievert?. <i>Radiology</i> , 2011, 261, 330-331.	7.3	3
115	The Yield of <sup>18</sup> F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1526-1534.	5.0	99
116	Lognormal Distribution of Cellular Uptake of Radiopharmaceuticals: Implications for Biologic Response in Cancer Treatment. <i>Journal of Nuclear Medicine</i> , 2011, 52, 501-503.	5.0	1
117	Fatal Heart Failure After a 26-Month Combination of Tyrosine Kinase Inhibitors in a Papillary Thyroid Cancer. <i>Thyroid</i> , 2011, 21, 451-454.	4.5	24
118	The Sentinel Node Procedure in Breast Cancer: Nuclear Medicine as the Starting Point. <i>Journal of Nuclear Medicine</i> , 2011, 52, 405-414.	5.0	82
119	Pulmonary Metastasis of Struma Ovarii. <i>Clinical Nuclear Medicine</i> , 2010, 35, 692-694.	1.3	15
120	The evolving role of PET/CT in breast cancer. <i>Nuclear Medicine Communications</i> , 2010, 31, 271-273.	1.1	19
121	Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 623-634.	6.4	31
122	<sup>18</sup> F-FDG PET/CT bone/bone marrow findings in Hodgkinâ€™s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1095-1105.	6.4	129
123	On the effectiveness of recombinant human TSH as a stimulating agent for <sup>131</sup> I treatment of metastatic differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2264-2266.	6.4	11
124	Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients. <i>Nuclear Medicine Communications</i> , 2010, 31, 1054-1058.	1.1	17
125	Absorbed <sup>18</sup> F-FDG Dose to the Fetus During Early Pregnancy: FIGURE 1.. <i>Journal of Nuclear Medicine</i> , 2010, 51, 803-805.	5.0	52
126	Calculation of electron dose to target cells in a complex environment by Monte Carlo code â€œCELLDOSEâ€œ. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 130-136.	6.4	20



#	ARTICLE	IF	CITATIONS
127	A low thyroglobulin level cannot be used to avoid adjuvant <sup>131</sup> I therapy after thyroidectomy for thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 169-171.	6.4	7
128	2009 EANM parathyroid guidelines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1201-1216.	6.4	272
129	<sup>18</sup> F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 137-144.	1.0	65
130	Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of <sup>18</sup> F-FDG PET studies. <i>Nuclear Medicine Communications</i> , 2009, 30, 926-933.	1.1	4
131	Hepatosplenic Candidiasis Imaged With F-18 FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2009, 34, 439-440.	1.3	34
132	IN VIVO QUANTIFICATION OF <sup>18</sup> F-FDG UPTAKE IN HUMAN PLACENTA DURING EARLY PREGNANCY. <i>Health Physics</i> , 2009, 97, 82-85.	0.5	18
133	Can we avoid inadvertent parathyroidectomy during thyroid surgery?. <i>In Vivo</i> , 2009, 23, 433-9.	1.3	15
134	[ <sup>123</sup> I]-FP-CIT and [ <sup>99m</sup> Tc]-HMPAO single photon emission computed tomography in a new sporadic case of rapid-onset dystoniaâ€“parkinsonism. <i>Journal of the Neurological Sciences</i> , 2008, 273, 148-151.	0.6	49
135	Estimation of the <sup>125</sup> I Dose to the Embryo Resulting from <sup>18</sup> F-FDG Administration During Early Pregnancy: FIGURE 1.. <i>Journal of Nuclear Medicine</i> , 2008, 49, 679-682.	5.0	39
136	CELLDOSE: A Monte Carlo Code to Assess Electron Dose Distributionâ€™S Values for <sup>131</sup> I in Spheres of Various Sizes. <i>Journal of Nuclear Medicine</i> , 2008, 49, 151-157.	5.0	53
137	Bone Metastases of Differentiated Thyroid Cancer: The Importance of Early Diagnosis and <sup>131</sup> I Therapy on Prognosis. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1902-1903.	5.0	21
138	Plasma Exchanges Overcome Persistent Iodine Overload to Enable <sup>131</sup> I Ablation of Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2008, 18, 469-472.	4.5	3
139	Slow Dynamic Lymphoscintigraphy Is Not a Reliable Predictor of Sentinel-Node Negativity in Cutaneous Melanoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 443-450.	1.0	6
140	Bone metastases of differentiated thyroid cancer: impact of early <sup>131</sup> I-based detection on outcome. <i>Endocrine-Related Cancer</i> , 2007, 14, 799-807.	3.1	60
141	Tomoscintigraphy Improves the Determination of the Embryologic Origin of Parathyroid Adenomas, Especially in Apparently Inferior Glands: Imaging Features and Surgical Implications. <i>Journal of Nuclear Medicine Technology</i> , 2007, 35, 135-139.	0.8	20
142	Scintigraphic Visualization of Glossal Thyroid Tissue During the Follow-up of Thyroid Cancer Patients. <i>Clinical Nuclear Medicine</i> , 2007, 32, 911-914.	1.3	10
143	Stimulation test in the follow-up of thyroid cancer: Plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values. <i>Nuclear Medicine Communications</i> , 2007, 28, 257-259.	1.1	10
144	Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine <sup>131</sup> I?. <i>Clinical Endocrinology</i> , 2007, 66, 329-334.	2.4	12

#	ARTICLE	IF	CITATIONS
145	Distant metastases of differentiated thyroid cancer: diagnosis, treatment and outcome. Nuclear Medicine Review, 2007, 10, 106-9.	0.5	9
146	Secondary ion mass spectrometry as a tool for investigating radiopharmaceutical distribution at the cellular level: the example of I-BZA and (14)C-I-BZA. Journal of Nuclear Medicine, 2005, 46, 1701-6.	5.0	16
147	Parathyroid Scintigraphy. , 2005, , .		1
148	Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 974-981.	6.4	85
149	Parathyroid gland radionuclide scanning methods and indications. Joint Bone Spine, 2002, 69, 28-36.	1.6	8
150	La scintigraphie parathyroïdienne et ses indications actuelles. Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54	0.0	3
151	Unilateral Surgery for Primary Hyperparathyroidism on the Basis of Technetium Tc 99m Sestamibi and Iodine 123 Subtraction Scanning. Archives of Surgery, 2000, 135, 1461.	2.2	47
152	Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. Lancet, The, 1999, 353, 2200-2204.	13.7	65
153	Tc-99m Sestamibi and I-123 Detection of a Parathyroid Adenoma in the Presence of a Cold Thyroid Nodule. Clinical Nuclear Medicine, 1997, 22, 258-260.	1.3	3
154	Mapping the cellular distribution of labelled molecules by SIMS microscopy. Biology of the Cell, 1992, 74, 81-88.	2.0	28
155	SIMS microscopy: a tool to measure the intracellular concentration of carbon 14-labelled molecules. Biology of the Cell, 1992, 74, 89-92.	2.0	13
156	Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help. Journal of Clinical Oncology, 0, , .	1.6	2